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August 23, 2011:988–92regime. Although data are inconclusive, various agents have been
experimented with to provide protection against ANT-induced
CMP both in animal models and humans (3,4).
Statins have been shown to decrease atherosclerosis-related
orbidity and mortality. It is currently accepted that statins do
xert protective cardiovascular effects not solely from their
ipid-lowering capacity. In this regard, antioxidative properties
re 1 of the main factors by which statins exert so-called
leiotropic effects. Because ANT-induced cardiotoxicity has
een shown to be sufficiently triggered by cardiac oxidative
tress and inflammation, in the present report it was hypothe-
ized that statins, by their pleiotropic effects, might prevent
NT-induced cardiotoxicity. In a unique animal model, Riad et
l. (5) have shown that pretreatment with fluvastatin attenuated
NT-induced CMP. They have demonstrated reduced oxida-
ive stress, enhanced expression of antioxidative enzyme mito-
hondrial superoxide dismutase 2, and reduced cardiac inflam-
ation shown by decreased tumor necrosis factor-alpha
xpression in fluvastatin-pretreated mice. They concluded that
his outcome resulted from antioxidant and anti-inflammatory
ffects of fluvastatin.
In the present study, although the inter-group difference on our
redefined primary endpoint of LV dysfunction did not reach
tatistical significance, we have shown that prophylactic use of
torvastatin could be effective in maintenance of LVEF in patients
reated with ANT. We proposed that this effect could be related to
leiotropic effects of statins.
The major limitations of the present study are small sample size,
ack of placebo group, and the limited measures of cardiac
ysfunction that were studied. Also, due to the short follow-up
eriod of the study, late CMP could not be assessed.
reatly hamper the apparent strength of their conclusion. Primar-Zeydin Acar, MD
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2009;69:695–9.Letters to the EditorThe Israel Screening Failure
Analyzing the Data to
Understand the Results
The recent paper by Steinvil et al. (1) raised our concern and
prompted the present considerations. The intriguing title conceals
the idea that pre-participation screening including 12-lead elec-
trocardiography is ineffective for modifying the occurrence of
sudden cardiac deaths (SCDs) in young athletes, in contrast with
previously reported Italian data (2).
The authors claim that the yearly incidence of SCDs has
emained unchanged (i.e., 2.54 to 2.66 per 100,000 persons) in the
eriods 1985 to 1996 and 1997 to 2009, despite implementation of
he screening program in Israel (1). Their conclusion was that
fforts to prevent SCDs in young athletes by the electrocardio-
raphic screening were worthless.
However, we believe that certain methodological limitations doily, both the number of cardiac events and the population of
competitive athletes at risk were only roughly estimated.
First, the number of SCDs was derived only from 2 Israel
newspapers, and not from a national prospective registry. News-
papers focus on fatalities occurring in elite/national-level profes-
sional athletes, whereas reports of SCDs in the much larger
population of adolescents/adults engaged in nonprofessional/
regional sports are usually overlooked. Moreover, an increase in the
number of sports-related fatal events in more recent years in
Western countries has been reported, a phenomenon that simply
reflects enhanced public recognition due to increased media
attention (3). This may also explain the relative lower prevalence of
fatal events reported in the past decades and confirms the unreli-
ability of estimating the time trend of SCDs in athletes based only
on media reporting.
Second, the population of competitive athletes at risk is not
known. Authors state that the number of registered competitive
athletes was 45,000 in 2009. They claim that proportion of
Israel population engaged in competitive sports remained un-
changed over time, but the actual size doubled, based not on
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records (1).
In conclusion, in this article, the incidence of SCDs was
alculated from an uncertain number of events over an estimated
umber of athletes. The lack of solid numbers for both the
umerator and denominator makes the death rates not reliable.
Moreover, we were surprised that results of the Israel screening
rogram were completely ignored: no information was provided
egarding the implementation of the national screening, the
umber of examined athletes, the proportion of disqualified ones,
nd the cardiac abnormalities discovered. In short, no data derived
rom the direct experience of sport physicians support the alleged
nefficacy of the screening program in Israel.
By comparison, the Italian data were gathered according to a
rospective study design with systematic investigation of all young
ndividuals (competitive athletes and sedentary controls) who died
uddenly. All of the hearts were examined according to a definite
rotocol by expert cardiovascular pathologists. Moreover, the number
f competitive athletes registered within the athletic sport organiza-
ions and undergoing the pre-participation screening program was
nown for certain. The large diversity of Israel and Italian screening
eports make their direct comparison inappropriate.
The Italian experience showed a significant decrease in mortal-
ty over the entire time period after the implementation of the
creening program (p for trend 0.001), through analysis of the
time trend of death rates with Poisson regression of the number of
SCDs in each year against the calendar year, including the log of
the amount of person-time at risk in each year as an offset term.
Poisson regression analysis of the mortality trend over 26 years
allowed the potential limitation of a relatively short pre-screening
period to be overcome.
Indeed, the comparison of the SCD trend between screened
athletes and unscreened nonathletes (i.e., a control population of
the same age from the same geographic area) during the same
study period provided compelling evidence of the selective decrease
in mortality in young athletes undergoing screening.
Although the authors’ aim to explain the trend of SCDs in
Israel athletes is laudable, their conclusion that the mortality rate in
young athletes cannot be changed by implementing pre-
participation screening is not supported by scientifically reliable
data.
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Media Reporting Bias Affects
Reported Sudden Death Rates
Steinvil et al. (1) are to be commended for bringing an important
problem into the spotlight. In the past 3 weeks in the United States
alone, there have been 5 deaths of student athletes. The current
practice of pre-participation history and physical examination does
not detect most of the athletes at risk of sudden cardiac death
(SCD). However, rather than give us guidance on how to identify
high-risk athletes, Steinvil et al. (1) have raised more questions.
First, their study is based on observational data and retrospective
analysis, which are appropriate for generating hypotheses but not
for drawing significant conclusions or recommending policy
changes. Furthermore, the data used were newspaper/media re-
ports, which have inherent limitations and could lead to informa-
tion bias. For instance, the deaths of less-successful athletes may be
under-reported in the media. It is unclear why the authors did not
use a more complete source for mortality data, such as the National
Center of Forensic Medicine, which was used for a previous similar
study in Israel (2).
Furthermore, the deaths reported in this study were only for
competitive athletes. The benefit of pre-participation screening
may lie among those who engage in physical activity on a
noncompetitive level, but such persons were excluded in this
analysis. Although Steinvil et al. (1) acknowledged this limitation,
they did not estimate its effects. In most populations, this cohort is
actually larger than the professional athletes. For instance, in a
report on SCD from 1974 to 2002 in the Israel military, there were
74 cases of SCD among Israeli soldiers ages 18 to 39 years (3).
These cases were not reported in the media, and yet these cases
represent young persons who were engaged in physical activity who
died suddenly.
Contrary to what Steinvil et al. (1) reported, the previous large
Italian study of SCD in school-age athletes (4) was a prospective
study, not a retrospective study, with superior sources of outcomes
data. Steinvil et al. (1) concluded that the results of the Italian
study were related to a natural variation in SCD incidence rates.
However, in the Italian study, incidence rates of SCD were also
collected for the unscreened nonathletic young population, and
this rate remained constant over the 25 observation years. We
think that it is more likely that the marked variation noted in the
incidence of SCD in the Steinvil et al. study is due to the source
of their data (i.e., that media reporting is related to what is
currently in “vogue” and that this reporting may not reflect the true
population incidence rate).
We agree with Steinvil et al. (1) that to prevent SCD in this
young population, we need to strive for a solution that is feasible
and cost-effective. However, we believe that we cannot continue
with the status quo. Young athletes continue to die suddenly, and
we need to do better with identifying persons at risk. We believe
that the solution will require new thinking, and we join the authors
in a call for further studies on this serious societal concern.
